The desirability of treatment of gout with agents which control hyperuricemia and reduce the metabolic pool of uric acid in the body by producing uric acid diuresis is well established. This form of treatment results in control of joint manifestations, reduction in size of tophi, and, in some cases, in improvement of renal manifestations.1 Salicylates,2 probenecid,3-5 cortisone analogues, phenylbutazone,6 and sulfinpyrazone7 have been used to this end. All these agents act similarly by inhibiting the renal tubular mechanism which is responsible for the reabsorption of uric acid filtered by the glomeruli.8,9
Recently, zoxazolamine, an agent originally introduced as a muscle relaxant, has been found to possess a potent uricosuric action.10,11 This drug is particularly interesting because of its chemical dissimilarity to the agents previously used. Burns et al.11 have reported studies on the metabolic fate of this drug and its effect on
RIVERA JV. Uricosuric Effects of Probenecid and Zoxazolamine in Gout: A Comparative Study. Arch Intern Med. 1961;108(4):512–518. doi:10.1001/archinte.1961.03620100004002
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: